Report of Adverse Events in Colombia: A Successful Case.
| Autor: | Moreno-Mattar O; National Food and Drug Surveillance Institute (INVIMA), Carrera 10 # 64, 28 Bogota, Colombia., Ramírez R; National Food and Drug Surveillance Institute (INVIMA), Carrera 10 # 64, 28 Bogota, Colombia., Alvarado A; National Food and Drug Surveillance Institute (INVIMA), Carrera 10 # 64, 28 Bogota, Colombia., Sierra F; National Food and Drug Surveillance Institute (INVIMA), Carrera 10 # 64, 28 Bogota, Colombia., Guzmán J; National Food and Drug Surveillance Institute (INVIMA), Carrera 10 # 64, 28 Bogota, Colombia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current drug safety [Curr Drug Saf] 2019; Vol. 14 (1), pp. 53-56. |
| DOI: | 10.2174/1574886313666181109150648 |
| Abstrakt: | Background: The Colombian National Food and Drug Surveillance Institute (INVIMA) is responsible for monitoring the safety and efficacy of medicines circulating the Colombian market. Discussion: This article summarizes the three key strategies the institution has implemented to strengthen the National Pharmacovigilance Program: improving the interaction and working relationship with regional health authorities, expanding the National Pharmacovigilance Network and implementing the electronic submission of adverse events. Conclusion: The number of adverse events reported in Colombia increased from 5,447 in 2013 to 95,658 in 2017, reaching a population-based reporting ratio within international standards (563 in 2016). (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|